Journal articles: 'Ortopedico Rizzoli'

1

Toni, Aldo, and Fabio Baruffaldi. "La telemedicina: sfida e opportunitÀ per l'Istituto Ortopedico Rizzoli." SALUTE E SOCIETÀ, no. 2 (September 2009): 172–75. http://dx.doi.org/10.3280/ses2009-su2014.

Full text

Abstract:

- During the last years of the 20th century the Istituto Ortopedico Rizzoli was involved in a significant innovation of the clinical process. professor Ardigň was a key player in that workplan of innovation, frequently driven by the development of Information and Communication technologies. Telemedicine represents a perfect example of his enthusiastic effort for the deployment of new technologies at the service of the citizen.Keywords: telemedicine, orthopaedics, information, communication, technologies, citizen.Parole chiave: telemedicina, ortopedia, information, communication, technologies, cittadini.

APA, Harvard, Vancouver, ISO, and other styles

2

Bacci, Gaetano, Stefano Ferrari, Franco Bertoni, Pietro Ruggieri, Piero Picci, Alessandra Longhi, Roberto Casadei, et al. "Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report." Journal of Clinical Oncology 18, no. 24 (December 15, 2000): 4016–27. http://dx.doi.org/10.1200/jco.2000.18.24.4016.

Full text

Abstract:

PURPOSE: To provide an estimate of long-term prognosis for patients with osteosarcoma of the extremity treated in a single institution with neoadjuvant chemotherapy and observed for at least 10 years. PATIENTS AND METHODS: Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM). Postoperatively, good responders (90% or more tumor necrosis) received the same three drugs used before surgery, whereas poor responders (less than 90% tumor necrosis) received ifosfamide and etoposide in addition to those three drugs. RESULTS: For the 164 patients who entered the study between September 1986 and December 1989, surgery was a limb salvage in 136 cases (82%) and a good histologic response was observed in 117 patients (71%). At a follow-up ranging from 10 to 13 years (median, 11.5 years), 101 patients (61%) remained continuously free of disease, 61 relapsed, and two died of ADM-induced cardiotoxicity. There were no differences in prognosis between good and poor responding patients. ADM-induced cardiotoxicity (six patients), male infertility (10 of the 12 assessable patients), and second malignancies (seven patients) were the major complications of chemotherapy. Despite the large number of limb salvages performed, only four local recurrences (2.4%) were registered. CONCLUSION: With an aggressive neoadjuvant chemotherapy, it is possible to cure more than 60% of patients with nonmetastatic osteosarcoma of the extremity and amputation may be avoided in more than 80% of them. Because local or systemic relapses, myocardiopathies, and second malignancies are possible even 5 years or more after the beginning of treatment, a long-term follow-up is recommended for these patients.

APA, Harvard, Vancouver, ISO, and other styles

3

GRANATA, C., S. GIANNINI, A. BALLESTRAZZI, and L. MERLINI. "Early surgery in Duchenne muscular dystrophy. Experience at Istituto Ortopedico Rizzoli, Bologna, Italy." Neuromuscular Disorders 4, no. 1 (January 1994): 87–88. http://dx.doi.org/10.1016/0960-8966(94)90053-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bonadies, Aldo, Rita Mancini, Marilia Maci, Chiara Gibertoni, and Anna Maria Petrini. "Laboratorio Unico Metropolitano: innovazione e alta tecnologia per un nuovo paradigma di medicina di laboratorio." MECOSAN, no. 115 (January 2021): 79–94. http://dx.doi.org/10.3280/mesa2020-115005.

Full text

Abstract:

Il Laboratorio Unico Metropolitano (LUM) e un intervento di programmazione sanitaria nato sulla spinta delle indicazioni della Regione Emilia- Romagna e volto a ridefinire le capacita produttive attraverso la riduzione delle duplicazioni. Il LUM e un esempio di integrazione in rete tra le strutture e soprattutto tra i professionisti che si occupano di salute. E il primo caso in Italia di cessione del ramo d'azienda tra Aziende Pubbliche: Azienda Ospedaliero-Universitaria Sant'Orsola-Malpighi (AOU), AUSL Imola, Istituto Ortopedico Rizzoli (IOR) hanno "ceduto" le risorse umane e tecnologiche, nonche i contratti di qualsiasi natura relativi alle attivita di diagnostica di laboratorio di patologia clinica, all'AUSL Bologna, individuata quale Azienda Capofila del progetto, presso la quale e localizzata la struttura del Laboratorio Unico.

APA, Harvard, Vancouver, ISO, and other styles

5

Boriani, S., R. Biagini, F. De Iure, I. Andreoli, L. Campanacci, M. Di Fiore, and A. Zanoni. "PRIMARY BONE TUMORS OF THE SPINE: A SURVEY OF THE EVALUATION AND TREATMENT AT THE ISTITUTO ORTOPEDICO RIZZOLI." Orthopedics 18, no. 10 (October 1995): 993–99. http://dx.doi.org/10.3928/0147-7447-19951001-09.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bianchi, G., C. Charoenlap, S. Cocchi, N. Rani, S. Campagnoni, A. Righi, T. Frisoni, and D. M. Donati. "Clear cell sarcoma of soft tissue: A retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli." European Journal of Surgical Oncology 40, no. 5 (May 2014): 505–10. http://dx.doi.org/10.1016/j.ejso.2014.01.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bacci, Gaetano, Piero Picci, Franco Gherlinzoni, Rodolfo Capanna, Pierina Calderoni, Carlo Putti, Antonia Mancini, and Mario Campanacci. "Localized Ewing's sarcoma of bone: Ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy." European Journal of Cancer and Clinical Oncology 21, no. 2 (February 1985): 163–73. http://dx.doi.org/10.1016/0277-5379(85)90168-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bacci, Gaetano, Stefano Ferrari, Franco Bertoni, Simonetta Rimondini, Alessandra Longhi, Patrizia Bacchini, Cristiana Forni, Marco Manfrini, Davide Donati, and Piero Picci. "Prognostic Factors in Nonmetastatic Ewing’s Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli." Journal of Clinical Oncology 18, no. 1 (January 1, 2000): 4. http://dx.doi.org/10.1200/jco.2000.18.1.4.

Full text

Abstract:

PURPOSE: The identification of prognostic factors in patients with nonmetastatic Ewing’s sarcoma could allow the use of risk-adapted therapeutic strategies of treatment. PATIENTS AND METHODS: Data on 359 patients with nonmetastatic Ewing’s sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered. The influence of clinical, hematologic, therapeutic, and histologic parameters on event-free survival was assessed. RESULTS: By univariate analysis, the following features were found to be associated with a poor prognosis: male sex (P < .02), age older than 12 years (P < .006), fever (P < .0001), anemia (P < .0025), high serum lactate dehydrogenase (LDH) level (P < .0001), axial location (P < .04), radiation therapy only for local control (P < .009), type of chemotherapy regimen (P < .0001), and poor chemotherapy-induced necrosis (P < .001). After multivariate analysis, the adverse independent prognostic factors were male sex (P < .04), age older than 12 years (P < .001), fever (P < .0002), anemia (P < .02), high serum LDH level (P < .0003), axial location (P < .02), and type of chemotherapy regimen (P < .0003). When the multivariate analysis was restricted to surgically treated patients, the adverse independent prognostic factors were poor chemotherapy-induced necrosis (P < .0001), fever (P < .015), anemia (P < .02), and high serum LDH level (P < .025). CONCLUSION: The prognosis in cases of nonmetastatic Ewing’s sarcoma is influenced by many different clinical and hematologic variables, all of which are to be considered when patients are being stratified according to the risk of relapse. In surgically treated patients, the most important prognostic factor is chemotherapy-induced necrosis.

APA, Harvard, Vancouver, ISO, and other styles

9

Bragonzoni, Laura, Giuseppe Barone, Francesco Benvenuti, Veronica Canal, Claudio Ripamonti, Sofia Marini, and Laura Dallolio. "A Randomized Clinical Trial to Evaluate the Efficacy and Safety of the ACTLIFE Exercise Program for Women with Post-menopausal Osteoporosis: Study Protocol." International Journal of Environmental Research and Public Health 17, no. 3 (January 28, 2020): 809. http://dx.doi.org/10.3390/ijerph17030809.

Full text

Abstract:

Osteoporosis (OP) is a systemic disease of the skeleton characterized by increased risk of fracture. There is a general consensus on the efficacy of physical activity in the prevention of bone loss, falls and fractures, but there is no agreement on the best setting to exercise. The aim of the study is to evaluate the efficacy of a 12-months exercise protocol for women with post-menopausal OP when administered as individual home training (IHT) versus gym group training (GGT). The study is a randomized trial with two parallel groups. Sedentary patients with primary post-menopausal osteoporosis are recruited at the Istituto Ortopedico Rizzoli of Bologna. In the first group, the 12-month ACTLIFE program is performed as IHT, while in the second as GGT. The program is aimed at improving joint mobility, muscle force, balance, motor coordination and endurance. The study is single blinded. Patients are assessed at baseline and after 6 and 12 months. The primary outcome is the modification of quality of life measured with the Short Osteoporosis Quality of Life Questionnaire (ECOS-16). The findings of this study will highlight advantages and disadvantages of exercising in the two different settings and provide evidence on how to increase physical activity in osteoporotic women.

APA, Harvard, Vancouver, ISO, and other styles

10

Gaetano Bacci, Stefano Ferrari, Ale. "Neoadjuvant Chemotherapy for Ewing's Sarcoma of Bone in Patients Older than Thirty-nine Years: Experience of Twenty-three Cases at the Istituto Ortopedico Rizzoli." Acta Oncologica 39, no. 1 (January 2000): 111–16. http://dx.doi.org/10.1080/028418600431076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bacci, Gaetano, Norman Jaffe, Ermanno Emiliani, James Van Horn, Marco Manfrini, Piero Picci, Franco Bertoni, Franco Gherlinzoni, and Mario Campanacci. "Therapy for primary non-Hodgkin's lymphoma of bone and a comparison of results with ewing's sarcoma. Ten years' experience at the Istituto Ortopedico Rizzoli." Cancer 57, no. 8 (April 15, 1986): 1468–72. http://dx.doi.org/10.1002/1097-0142(19860415)57:8<1468::aid-cncr2820570806>3.0.co;2-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Bacci, Gaetano, Norman Jaffe, Ermanno Emiliani, Rodolfo Capanna, Pierina Calderoni, Piero Picci, Franco Bertoni, Franco Gherlinzoni, and Mario Campanacci. "Staging, Therapy and Prognosis of Primary Non-Hodgkin's Lymphoma of Bone and a Comparison of Results with Localized Ewing's Sarcoma: Ten Years Experience at the Istituto Ortopedico Rizzoli." Tumori Journal 71, no. 4 (August 1985): 345–54. http://dx.doi.org/10.1177/030089168507100405.

Full text

Abstract:

Thirty consecutive cases of localized primary non-Hodgkin's lymphoma of bone (PNHLB) were treated in a 10-year period at the Istituto Ortopedico Rizzoli with localized radiation (4 cases) and localized radiation and adjuvant chemotherapy (26 cases). The doses of radiation varied from 3000-4500 rad. A variety of staging procedures evolving with new diagnostic techniques over the 10 years were performed. Adjuvant chemotherapy comprised two different regimens of vincristine, adriamycin and cyclophosphamide. Twenty-four of the 26 patients (92 %) have been free of disease with a median follow-up of 75.5 months (18-144 months). Two patients developed meningeal involvement and one patient, treated with radiation therapy only, developed a local recurrence. The results are compared to the management of 68 Ewing's sarcoma patients treated during the same period. Here, higher doses of localized radiation therapy (approximately 5000 rad) and similar adjuvant chemotherapy were administered. The survival was 32 % (22/68) with a higher incidence of local recurrence (21 %). These data indicate that PNHLB should be considered a separate entity from Ewing's sarcoma and can be treated successfully with lower doses of radiation to the primary tumor and adjuvant chemotherapy. The observations are also compared to a variety of other biological characteristics of Ewing's sarcoma. Since only two patients developed meningeal relapse, our experience does not permit a firm recommendation for routine prophylactic treatment of the central nervous system in PNHLB.

APA, Harvard, Vancouver, ISO, and other styles

13

Leardini, Alberto, Stefano Durante, Claudio Belvedere, Paolo Caravaggi, Claudio Carrara, Lisa Berti, Giada Lullini, et al. "Weight-bearing CT Technology in Musculoskeletal Pathologies of the Lower Limbs: Techniques, Initial Applications, and Preliminary Combinations with Gait-Analysis Measurements at the Istituto Ortopedico Rizzoli." Seminars in Musculoskeletal Radiology 23, no. 06 (November 19, 2019): 643–56. http://dx.doi.org/10.1055/s-0039-1697939.

Full text

Abstract:

AbstractMusculoskeletal radiology has been mostly limited by the option between imaging under load but in two dimensions (i.e., radiographs) and three-dimensional (3D) scans but in unloaded conditions (i.e., computed tomography [CT] and magnetic resonance imaging in a supine position). Cone-beam technology is now also a way to image the extremities with 3D and weight-bearing CT. This article discusses the initial experience over a few studies in progress at an orthopaedic center. The custom design of total ankle replacements, the patellofemoral alignment after medial ligament reconstruction, the overall architecture of the foot bones in the diabetic foot, and the radiographic assessment of the rearfoot after subtalar fusion for correction of severe flat foot have all taken advantage of the 3D and weight-bearing feature of relevant CT scans. To further support these novel assessments, techniques have been developed to obtain 3D models of the bones from the scans and to merge these with state-of-the-art gait analyses.

APA, Harvard, Vancouver, ISO, and other styles

14

Morini, Danilo. "Ardigň, Commissario Straordinario dell'IRCCS Istituti Ortopedici "Rizzoli"." SALUTE E SOCIETÀ, no. 2 (September 2009): 192–96. http://dx.doi.org/10.3280/ses2009-su2018.

Full text

Abstract:

- The author, after remembering Achille Ardigň for his first and youthful opportunity to meet in 1952 and for some joyful moments of relationships between Ardigň and Giuseppe Dossetti in Rossena Castle in 1951, examines and describes the activities of Ardigň as Extraordinary Commissioner of Rizzoli, with particularly regards demonstrated to the needs of the hospital and the establishment and operation of the Mixed Committee for the quality control by the side of the consumers.Keywords: Achille Ardigň, Extraordinary Commissioner, Rizzoli, hospital, side of the consumers, quality control.Parole chiave: Achille Ardigň, Commissario straordinario, Rizzoli, ospedale, dal lato degli utenti, controllo qualitÀ.

APA, Harvard, Vancouver, ISO, and other styles

15

Abate, Massimo Eraldo, Anna Paioli, Marilena Cesari, Alessandra Longhi, Emanuela Palmerini, Elisabetta Setola, Elisa Carretta, et al. "Toxicity and efficacy of busulfan-melphalan (BuMel) compared to treosulfan-melphalan (TreoMel) high dose chemotherapy (HDCT) consolidation in high-risk Ewing sarcoma (ES): A 12-year monoinstitutional experience." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e22507-e22507. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e22507.

Full text

Abstract:

e22507 Background: We compared toxicity and outcomes of BuMel and TreoMel HDCT consolidation with stem cell rescue in high-risk ES pts prospectively treated in 5 consecutive trials at the Istituto Ortopedico Rizzoli, Bologna, Italy. Methods: Eligible pts had histologically proven diagnosis of ES, high-risk disease defined as localized disease with poor histological/radiological response to standard chemotherapy or lung/pleural metastases or extra-pulmonary metastases or relapsed disease, were aged < 40. All pts received previous standard chemotherapy (vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide actinomycin-D) and surgery and/or radiation therapy (RT) as local treatment. From June 1, 2011, TreoMel was used instead of BuMel to avoid potential severe complications related to busulfan, as in case of previous RT on axial skeleton/pelvis. Pts with lung metastases received lung irradiation 12-15 Gy at least 2 months after HDCT. Results: Between January 1, 2007, and September 30, 2018, 98 pts received BuMel or TreoMel: 52 pts with localized disease (7 TreoMel), 26 pts with lung/pleural metastases (5 TreoMel), 10 pts with extra-pulmonary metastases (4 TreoMel) and 10 pts with relapsed disease (1 TreoMel). Median age was 18 yrs (range 3-39 yrs). 14 out of 17 TreoMel pts received previous RT on axial skeleton/pelvis. Median follow up is 4.2 yrs (range 10 mo. - 12 yrs). Pts treated with TreoMel showed a significant lower incidence of grade 3-4 stomatitis (p = < 0.001) and of all grade ≥ 3 non-hematological toxicities (p = < 0.001). One pt died of BuMel-related toxicity (sinusoidal obstruction syndrome/veno-occlusive disease) and none after TreoMel. For localized ES, the 5yr-EFS was 66.7% (95%CI, 47.9-78) for BuMel pts and 66.7% (95CI%, 19.5-90.4) for TreoMel pts. Conclusions: In high-risk ES, TreoMel is significantly less toxic then BuMel. Combining RT on central/axial sites and TreoMel is feasible. In localized ES, results show similar 5yr-EFS between BuMel and TreoMel. TreoMel could be used instead of BuMel when busulfan is contraindicated.

APA, Harvard, Vancouver, ISO, and other styles

16

Palmerini, Emanuela, Stefano Pengo, Robert G. Maki, Eric L. Staals, Angela Cioffi, Marco Alberghini, Piero Picci, et al. "Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 10022. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10022.

Full text

Abstract:

10022 Background: Tenosynovial giant cell tumor (TGCT) is a rare, usually benign neoplasm of synovium and tendon sheath. TGCT is classified as localized or diffuse according to the extent of synovial involvement. Surgery is the primary treatment, but the recurrence rate is high, with possible multiple recurrences, joint function deterioration and decline in quality of life. Recent data suggest a role for TKIs in advanced disease. In order to identify prognostic factors for recurrence, a retrospective pooled analysis was carried out in three institutions (Istituto Ortopedico Rizzoli, Bologna, Italy; Istituto Nazionale Tumori, Milano, Italy; Memorial Sloan Kettering Cancer Center, New York, USA). Methods: Clinical charts and pathology reports of patients (pts) treated in the period 1998-2008 were examined. Results: The study included 313 pts, 177 F and 136 M; median age: 36 years (range: 11-89 years). Most (64%) pts had tumors in the knee (15% ankle, 11% hip, 10% other). Tumor size was: <2 cm in 24% of pts, 2-5 cm in 44%, >5 cm in 32%. A diffuse pattern was reported in 69% of pts. The resection status was available in 289 pts: 51% had R0 surgery, 28% R1 and 21% R2. No metastases were documented. Local recurrence was reported in 76 pts (median time to recurrence: 15.7 months). With a median follow-up of 4.2 years, 5-year local recurrence-free survival (LRFS) was 66% (95% CI: 59 - 73). Size (< 2 cm 80% vs. 2-5 cm 67% vs. >5 cm 62%, p=0.04), gender (F 73% vs. M 56%, p=0.02), type (localized 78% vs. diffuse 61%, p=0.02), and resection status (R0 76% vs. R1 55%, vs. R2 57%, p=0.002) influenced 5-year LRFS, whereas age, tumor location and bone involvement did not. The 5-year 2nd LRFS was 43% (95% CI: 28 - 59). Multiple (2 to 5) local recurrences were observed in 39% of relapsed patients. Conclusions: The study confirms TGCT propensity to multiple local recurrences. Diffuse type, suboptimal surgery, male gender and larger tumors increase the recurrence risk. In order to improve the probability of local control, studies addressing the role of TKIs could be considered in subsets of patients.

APA, Harvard, Vancouver, ISO, and other styles

17

Stacchiotti, S., S. Lo Vullo, M. Mercuri, L. Mariani, M. Alberghini, S. Pilotti, S. Ferrari, P. G. Casali, A. Gronchi, and P. Picci. "Chordoma of the mobile spine: A retrospective analysis on 146 patients from two reference centers." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 10517. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.10517.

Full text

Abstract:

10517 Background: The natural history of chordoma is still poorly known. Methods: We reviewed a large series of patients (pts) from two major reference centers for chordoma. All pts presenting at Istituto Ortopedico Rizzoli, Bologna, and Istituto Nazionale Tumori, Milan, Italy, over 25 years, were reviewed. Clinical and pathologic characteristics were recorded. Local recurrence, distant metastasis, and overall survival (OS) were analyzed both from time of diagnosis and from time of local recurrence/distant metastasis. A multivariable analysis to identify independent prognostic factors was carried out. PDGFR and brachyury expression analysis is ongoing. Results: One hundred forty-six consecutive pts were identified (sacrum 79%, lumbar spine 15%, cervical-dorsal spine 6%; extension at diagnosis: localized 90%, locally-advanced 5%, metastatic 5%; median size 10 cm, IQ range: 6–14). Median follow-up was 140 months (IQ range: 80–205). The 5/10-year OS, local relapse-free survival (LRFS) and distant relapse-free survival (DRFS) were respectively: 76/52%, 51/32%, 86/72%. For pts with primary disease, size independently predicted OS (p-value: 0.004), LRFS (p-value: 0.006) and DRFS (p-value: 0.02), while surgical margins independently predicted only LRFS (p-value: 0.0001) with a trend for OS (p-value 0.1007). Radiotherapy performed in 44 pts did not influence LRFS nor OS, but only 9 pts received >60 Gy. The 5/10-year OS, LRFS, DRFS after the first local relapse were 54/24%, 50/45%, 64/61%. Size of the recurrence and quality of surgical margins did not influence post-relapse OS. The 5/10-year OS after the second local relapse were 20/0%. The overall incidence of metastases was 32% (commonest site: lung). The 5/10-year post-metastases OS was 35/0% (median 3 years). Results on PDGFR and brachyury expression will be provided. Conclusions: Tumor size and surgical margins affected outcome only on initial presentation. Incidence of distant metastases was higher than expected, although with a more indolent course than generally supposed. In spite of its indolent behavior, long-term prognosis was poor, with 26% of pts being continuously disease-free at 10 years. This series may provide an external control for studies on novel targeted agents, which are proving effective in such a rare tumor. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

18

Marchi, M., M. C. Malaguti, and C. Monti. "Problemi di diagnosi differenziale nelle metastasi solitarie del rachide cervicale." Rivista di Neuroradiologia 8, no. 2 (April 1995): 207–14. http://dx.doi.org/10.1177/197140099500800212.

Full text

Abstract:

La diagnosi differenziale tra lesione neoplastica primitiva benigna o maligna e metastasi solitaria nei pazienti con anamnesi oncologica negativa è estremamente difficoltosa ma rappresenta un'esigenza fondamentale per una corretta strategia terapeutica. Una revisione della casistica degli Istituti Ortopedici Rizzoli raccolta negli ultimi 4 anni, ha dimostrato che solo in 18 casi di pazienti di età compresa fra 50 e 80 anni si è posto il problema diagnostico differenziale menzionato e che esso, nonostante le informazioni ottenute con la RC, la TC e la RM, è stato risolto solo ricorrendo alla biopsia, o TC guidata o chirurgica. È stato possibile tuttavia rilevare, specie utilizzando la TC con mezzo di contrasto, alcune caratteristiche semeiologiche delle lesioni riscontrate (10 metastasi, 4 cordomi, 2 plasmocitomi, 1 linfoma e 1 emangiopericitoma) che consentono di formulare un orientamento diagnostico; la TC e la RM si sono mostrate in tutti i casi utili per realizzare una corretta stadiazione loco-regionale.

APA, Harvard, Vancouver, ISO, and other styles

19

Monti, C., M. C. Malaguti, and M. Marchi. "La patologia della colonna dell'anziano." Rivista di Neuroradiologia 7, no. 3_suppl (October 1994): 65–88. http://dx.doi.org/10.1177/19714009940070s309.

Full text

Abstract:

La patologia della colonna dell'anziano, intendendo arbitrariamente con questo termine soggetti di età superiore ai 60 anni, è costituita per lo più da lesioni degenerative osteo-disco-articolari, dalla osteoporosi e dalle sue complicanze. Dalla revisione di 1.000 esami di tomografia computerizzata della colonna in pazienti di età superiore a 60 anni gli Autori infatti hanno posto diagnosi in 808 casi di malattia degenerativa e di osteoporosi e in 192 casi hanno ritrovato altre patologie che, pur non essendo di esclusiva pertinenza dell'anziano, mostrano una netta predilezione per questa fascia di età. In 27 pazienti fu posta diagnosi di metastasi ed il dato, epidemiologicamente non significativo, è da porsi in relazione al carattere monospecialistico degli Istituti Ortopedici Rizzoli. In 93 casi fu posta diagnosi di tumore osseo primitivo benigno rappresentato dall'emangioma nelle sue varietà asintomatica e compressiva; i 43 casi di tumori ossei primitivi maligni sono da ascrivere in ordine decrescente al mieloma, al cordoma, ai linfomi e a rarissimi casi di emangioendotelioma. In 21 pazienti fu posta diagnosi di spondilodiscite e in 8 di malattia di Paget. Gli autori descrivono le caratteristiche clinico-radiologiche di queste lesioni enfatizzando il ruolo della tomografia computerizzata e della risonanza magnetica non solo nella individuazione e precisazione della lesione ma anche nel bilancio loco-regionale ed infine sottolineano la difficoltà della diagnosi differenziale tra metastasi, tumori primitivi maligni talora con le spondilodisciti e la malattia di Paget per cui spesso è indispensabile il ricorso alla biopsia TC-guidata.

APA, Harvard, Vancouver, ISO, and other styles

20

Wachowsky, M., S. D'Souza, and T. Wirth. "Comparison of gait kinematics in children using the calibration anatomical system technique based model (CAST), Instituti Ortopedici Rizzoli (IOR) model and modified Helen Hayes (MHH) model." Gait & Posture 42 (September 2015): S98. http://dx.doi.org/10.1016/j.gaitpost.2015.06.179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Chiodoni, Claudia, Maria Teresa Di Martino, Francesca Zazzeroni, Michele Caraglia, Massimo Donadelli, Stefania Meschini, Carlo Leonetti, and Katia Scotlandi. "Correction to: Cell communication and signaling: how to turn bad language into positive one." Journal of Experimental & Clinical Cancer Research 38, no. 1 (October 25, 2019). http://dx.doi.org/10.1186/s13046-019-1431-5.

Full text

Abstract:

In the original publication of this article, [1] the affiliation for Katia Scotlandi needs to be revised, because the author prefers using its Italian name: Experimental Oncology Lab, Experimental Oncology Lab, CRS Development of Biomolecular Therapies, IRCCS Istituto Ortopedico Rizzoli. We apologize for any confusion this may have caused.

APA, Harvard, Vancouver, ISO, and other styles

22

Rolli, Maurizia, Elisa Porcu, Patrizio Di Denia, Annella Mingazzini, and Luca Bianciardi. "Informatizzazione della checklist per la sicurezza in sala operatoria e i risultati raggiunti presso l'Istituto Ortopedico Rizzoli di Bologna." Pratica Medica & Aspetti Legali 10, no. 3 (November 29, 2016). http://dx.doi.org/10.7175/pmeal.v10i3.1276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Ortopedico Rizzoli'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles